Activation and detoxication of aflatoxin B1

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 402, Issue 1-2, 1998, Pages 121-128

  Guengerich, F Peter ^a,b   Johnson, William W ^a,b   Shimada, Tsutomu ^a,b   Ueng, Yune Fang ^a,b   Yamazaki, Hiroshi ^a,b   Langouët, Sophie ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OSAKA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

Author keywords

Aflatoxin B1; Cytochrome P450; DNA interaction; Epoxide hydrolase; Glutathione transferase; Kinetics

Indexed keywords

AFLATOXIN B1; GLUTATHIONE TRANSFERASE; OLTIPRAZ;

CHEMICAL CARCINOGENESIS; CONFERENCE PAPER; DETOXIFICATION; DRUG DNA INTERACTION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL; PRIORITY JOURNAL;

AFLATOXIN B1; ANIMALS; BIOTRANSFORMATION; CARCINOGENS; CYTOCHROME P-450 ENZYME SYSTEM; DNA; EPOXIDE HYDROLASES; HUMANS; METABOLIC DETOXICATION, DRUG;

EID: 0032543419     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(97)00289-3     Document Type: Conference Paper

References (67)

1. [1] R.W. Detroy, E.B. Lillehoj, A. Ciegler, Aflatoxin and related compounds, in: A. Ciegler, S. Kadis, S.J. Ajl (Eds.), Microbial Toxins, Vol. 6, Academic Press, New York, 1971, pp. 3-178.
2. [2] Aflatoxin: Scientific Background, Control, and Implications, Academic Press, New York, 1969.
3. [3] G.N. Wogan, Aflatoxins as risk factors for hepatocellular carcinoma in humans, Cancer Res. 52 (1992) 2114s-2118s, Suppl.
4. [4] J.G. Heathcoate, J.R. Hibbert, Aflatoxins: Chemical and Biological Aspects, Elsevier, New York, 1978.
5. [5] W.F. Busby, G.N. Wogan, Aflatoxins, in: C.E. Searle (Ed.), Chemical Carcinogens, 2nd edn., Am. Chem. Soc., Washington, DC, 1984, pp. 945-1136.
6. 1 by different species, Risk Anal. 10 (1990) 539-559.
7. 1 to a reactive derivative toxic to Salmonella typhimurium TA 1530, Cancer Res. 32 (1972) 2058-2066.
8. [8] M.G. Bolton, A. Muñoz, L.P. Jacobson, J.D. Groopman, Y.Y. Maxuitenko, B.D. Roebuck, T.W. Kensler, Transient intervention with oltipraz protects against aflatoxin-induced hepatic tumorigenesis, Cancer Res. 53 (1993) 3499-3504.
9. NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver, Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 462-465.
10. [10] T. Shimada, M. Iwasaki, M.V. Martin, F.P. Guengerich, Human liver microsomal cytochrome P450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA1535/pSK1002, Cancer Res. 49 (1989) 3218-3228.
11. 7 adducts and inducing different genetic responses, Chem. Res. Toxicol. 2 (1989) 114-122.
12. 1, Chem. Res. Toxicol. 5 (1992) 202-210.
13. 1: a new metabolite, Chem. Res. Toxicol. 5 (1992) 333-335.
14. 1 exo and endo epoxides by rat and human glutathione S-transferases, Chem. Res. Toxicol. 5 (1992) 470-478.
15. 1: mechanistic studies, J. Am. Chem. Soc. 116 (1994) 1603-1609.
16. [16] T. Shimada, E.M.J. Gillam, P. Sandhu, Z. Guo, R.H. Tukey, F.P. Guengerich, Activation of procarcinogens by human cytochrome P450 enzymes expressed in Escherichia coli: simplified bacterial systems for genotoxicity assays, Carcinogenesis 15 (1994) 2523-2529.
17. 1 by bacterial recombinant human cytochrome P450 enzymes, Chem. Res. Toxicol. 8 (1995) 218-225.
18. 1 exo-8,9-oxide and rearrangement of the dihydrodiol, J. Am. Chem. Soc. 118 (1996) 8213-8220.
19. [19] Y.-F. Ueng, T. Kuwabara, Y.-J. Chun, F.P. Guengerich, Cooperativity in oxidations catalyzed by cytochrome P450 3A4, Biochemistry 36 (1997) 370-381.
20. 1 8,9-exo-epoxide catalyzed by rat and human glutathione transferases: estimation of kinetic parameters, Biochemistry 36 (1997) 3056-3060.
21. [21] W.W. Johnson, Y.-F. Ueng, H. Yamazaki, T. Shimada, F.P. Guengerich, Role of microsomal epoxide hydrolase in the hydrolysis of aflatoxin B1 8,9-epoxide, Chem. Res. Toxicol. 10 (1997) 672-676.
22. 1 exo-8,9-epoxide with DNA: kinetic analysis of covalent binding and DNA-induced hydrolysis, Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 6121-6125.
23. 1 adduct formed by hamster and rat liver microsomes in vitro, Biochem. Biophys. Res. Commun. 53 (1973) 1260-1267.
24. 1 in vitro by rat liver microsomes, FEBS Lett. 101 (1979) 382-386.
25. 1-DNA or -ribosomal RNA adducts formed in hepatic microsome-mediated reactions and in rat liver in vivo, Cancer Res. 37 (1977) 4430-4438.
26. 1 in vitro, Proc. Natl. Acad. Sci. U.S.A. 74 (1977) 1870-1874.
27. 1, Biochem. J. 210 (1983) 227-233.
28. 1 and some of its esters, Carcinogenesis 1 (1980) 79-90.
29. 1: the ultimate carcinogenic species, J. Am. Chem. Soc. 110 (1988) 7929-7931.
30. 1, Carcinogenesis 6 (1985) 1227-1229.
31. 1 by lipoxygenases, prostaglandin H synthase and cytochrome P450 monooxygenase in guinea-pig tissues, Carcinogenesis 13 (1992) 533-539.
32. 1 by human liver microsomes: role of cytochrome P450 IIIA enzymes, Toxicol. Appl. Pharmacol. 108 (1991) 436-447.
33. 1, Cancer Res. 54 (1994) 101-108.
34. 1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4, Toxicol. Appl. Pharmacol. 141 (1996) 595-606.
35. [35] T. Shimada, H. Yamazaki, M. Mimura, Y. Inui, F.P. Guengerich, Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians, J. Pharmacol. Exp. Ther. 270 (1994) 414-423.
36. 2 by various inbred strains of mice, Mol. Pharmacol. 18 (1980) 296-303.
37. 1-4-hydroxylase, J. Biol. Chem. 263 (1988) 12187-12189.
38. [38] L. Lin, F. Yang, Z. Ye, E. Xu, C. Yang, C. Zhang, D. Wu, D.W. Nebert, Case-control study of cigarette smoking and primary hepatoma in an aflatoxin-endemic region of China: a protective effect, Pharmacogenetics 1 (1991) 79-85.
39. 1 in rabbit lung and liver, Carcinogenesis 11 (1990) 823-827.
40. 1 biotransformation in rabbit pulmonary and hepatic microsomes, Toxicology 74 (1992) 19-32.
41. 2 by animal and human liver, Cancer Res. 38 (1978) 999-1002.
42. 7 adducts by aflatoxin epoxides, Chem. Res. Toxicol. 3 (1990) 254-261.
43. 1 with guanines in different DNA sequences, Biochemistry 27 (1988) 472-481.
44. 1 in different DNA sequences, J. Biomol. Struct. Dyn. 5 (1988) 1237-1257.
45. 2, Biochemistry 29 (1990) 10438-10448.
46. [46] G. Lamm, G.R. Pack, Acidic domains around nucleic acids, Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 9030-9033.
47. [47] G. Lamm, L. Wong, G.R. Pack, DNA-mediated acid catalysis: calculations of the rates of DNA-catalyzed hydrolyses of diol epoxides, J. Am. Chem. Soc. 118 (1996) 3325-3331.
48. 1 in isolated rat hepatocytes, Biochem. Biophys. Res. Commun. 110 (1983) 668-674.
49. 1, Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 2384-2387.
50. [50] H.-F. Tzeng, L.T. Laughlin, S. Lin, R.N. Armstrong, The catalytic mechanism of microsomal epoxide hydrolase involves reversible formation and rate-limiting hydrolysis of the alkyl-enzyme intermediate, J. Am. Chem. Soc. 118 (1996) 9436-9437.
51. 1, Pharmacol. Ther. 50 (1991) 443-472.
52. 1, J. Biol. Chem. 269 (1994) 20707-20717.
53. 1 metabolism in human hepatocytes in primary culture, Cancer Res. 55 (1995) 5574-5579.
54. [54] Y.H. Liu, J. Taylor, P. Linko, G.W. Lucier, C.L. Thompson, Glutathione S-transferase m in human lymphocyte and liver: role in modulating formation of carcinogen-derived DNA adducts, Carcinogenesis 12 (1991) 2269-2275.
55. 1 in vivo in rats, Carcinogenesis 8 (1987) 819-824.
56. [56] C. Hassett, L. Aicher, J.S. Sidhu, C.J. Omiecinski, Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants, Hum. Mol. Genet. 3 (1994) 421-428.
57. [57] P. Talalay, R.P. Batzinger, A.M. Benson, E. Bueding, Y.N. Cha, Biochemical studies on the mechanisms by which dietary antioxidants suppress mutagenic activity, Adv. Enzyme Regulation 17 (1979) 23-36.
58. 1 to rat liver macromolecules by phenobarbitone pretreatment, Biochem. Pharmacol. 24 (1975) 1553-1556.
59. 1 toxicity: effect of pretreatment of rats with phenobarbital and 3-methylcholanthrene on aflatoxin toxicity, Toxicol. Appl. Pharmacol. 34 (1975) 128-142.
60. [60] T.W. Kensler, Oltipraz: Clinical opportunities for cancer chemoprevention, Abstracts, 5th Int. Conf. Antimutagenesis Anticarcinogenesis, Okayama, Japan, 2-6 December 1996.
61. 1-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): predictive role for short-term molecular dosimetry, Cancer Res. 51 (1991) 5501-5506.
62. [62] F. Morel, O. Fardel, D.J. Meyer, S. Langouët, K.S. Gilmore, C.P.D. Tu, T.W. Kensler, B. Ketterer, A. Guillouzo, Preferential increase of glutathione S-transferase a transcripts in cultured human hepatocytes by phenobarbital, 3-methylcholanthrene, and dithiolethiones, Cancer Res. 53 (1993) 231-234.
63. [63] T.M. Buetler, T.K. Bammler, J.D. Hayes, D.L. Eaton, Oltipraz-mediated changes in aflatoxin B1 biotransformation in rat liver: implications for human chemointervention, Cancer Res. 56 (1996) 2306-2313.
64. [64] S. Langouët, K. Mahéo, F. Berthou, D. Lagadic-Gossmann, D. Glaise, B. Coles, B. Ketterer, A. Guillouzo, Effects of administration of the chemoprotective agent oltipraz on CYP1A and CYP2B in rat liver and rat hepatocytes in culture, Carcinogenesis 18 (1997) 1343-1349.
65. [65] E. Bueding, R.P. Batzinger, Y.N. Cha, P. Talalay, C.J. Molineaux, Protection from mutagenic effects of antischistosomal and other drugs, Pharmacol. Rev. 30 (1979) 547-554.
66. [66] Y. Zhang, P. Talalay, C.G. Cho, G.H. Posner, A major inducer of anticarcinogenic protective enzyme from broccoli: isolation and elucidation of structure, Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 2399-2403.
67. [67] K. Maheo, F. Morel, S. Langouët, A. Guillouzo, F.P. Guengerich, K. Kramer, B. Ketterer, Action of sulforaphane on enzymes of both carcinogen activation and detoxification in primary hepatocytes from rat and man, Proc. Am. Assoc. Cancer Res. 38 (1997) 370.